Market Research Report
Contact Dermatitis (CD) - Market Insights, Epidemiology and Market Forecast - 2030
|Contact Dermatitis (CD) - Market Insights, Epidemiology and Market Forecast - 2030|
DelveInsight Business Research LLP
Content info: 200 Pages
Delivery time: 2-10 business days
DelveInsight's 'Contact Dermatitis (CD) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Contact Dermatitis (CD), historical and forecasted epidemiology as well as the Contact Dermatitis (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Contact Dermatitis (CD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Contact Dermatitis (CD) market size from 2017 to 2030. The report also covers current Contact Dermatitis (CD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Contact Dermatitis (CD) Overview
Contact dermatitis (CD) is a type of eczema triggered by contact with a particular substance in the environment that the person is allergic to, it may react by causing the skin to itch and become red. Eczema is the name for a group of conditions that cause skin to become dry and irritated. CD usually improves or clears up completely if the substance causing the problem is identified and avoided. Treatments are also available to help ease the symptoms.
CD is a common inflammatory skin condition characterized by erythematous and pruritic skin lesions that occur after contact with a foreign substance. The most common substances that cause CD include poison ivy, nickel, and fragrances. CD usually leads to erythema and scaling with visible borders. Itching and discomfort may also occur.
Clinical symptoms depend primarily on whether the dermatitis is acute or chronic, as well as on the toxin involved, type of contact, pathomechanism, and localization, among other factors. Although all types of dermatitis generally share common features, the classic eczematous stages in CD are most readily identifiable.
Acute CD is characterized by pathological symptoms over the entire lesion:
CD is a common skin problem occurring in 15-20% of people. Irritant Contact Dermatitis (ICD) is more common (80%) and can occur in anyone, especially after repeated exposure. Allergic contact dermatitis (ACD), on the other hand, is seen in genetically predisposed and previously sensitized individuals who react to even low concentrations of the agent. Cosmetics, medicines, clothes dyes, as well as foods, rubber and poison ivy are common causes of ACD. Any topical cream or ointment may contain chemicals that irritate the skin.
Contact Dermatitis (CD) Diagnosis
The diagnosis of CD is most often made with history and physical examination findings. Irritant and allergic CD may be complicated by bacterial superinfection, and bacterial culture should be considered with the presence of exudate, weeping, and crusting. A potassium hydroxide (KOH) preparation is useful if tinea or Candida infection is suspected, because these fungal infections can have erythema and scaling similar to contact dermatitis. If the KOH preparation has negative results but a fungal etiology is still suspected, a fungal culture should be sent for laboratory testing. Dermoscopy and microscopy can be used to look for scabies and mites.
When a possible causative substance is known, the first step in confirming the diagnosis is observing whether the problem resolves with avoidance of the substance. If avoidance and empiric treatment do not resolve the dermatitis or the allergen remains unknown, patch testing may be indicated. In one study, patch testing had a sensitivity and specificity of between 70-80%. However, it is expensive and time-consuming, and prohibits the patient from showering (a "sponge bath" technique may be used). Patch testing should not be confused with other types of allergy testing. Skin prick and radio-allergosorbent tests are used for the diagnosis of type I hypersensitivity, such as respiratory, latex, and food allergies, but not for contact dermatitis.
In some cases, a repeated open application test (ROAT) is useful, particularly to assess cosmetics. A ROAT involves reapplying the substance onto the same area of skin twice a day for 7 days, to see how the patients' skin reacts. This is a particularly useful way for anyone to check their cosmetics at home for reactions.
Contact Dermatitis (CD) Treatment
In patients with contact dermatitis, the priority is to identify and avoid the causative substance. Cool compresses can soothe the symptoms of acute contact dermatitis, and calamine lotion and colloidal oatmeal baths may help dry and soothe acute, oozing lesions.
Localized acute allergic CD lesions are successfully treated with mid- or high-potency topical steroids, such as triamcinolone 0.1% (Kenalog, Aristocort) or clobetasol 0.05% (Temovate). On areas with thinner skin (e.g., flexural surfaces, eyelids, face, anogenital region), lower-potency steroids, such as desonide ointment (Desowen), can be helpful and minimize the risk of skin atrophy. There are insufficient data to support the use of topical steroids for irritant contact dermatitis. However, because it is difficult to clinically distinguish between allergic and irritant contact dermatitis, these agents are often used successfully for the irritant form as well.
Till date, there is no approved therapy specific for CD. The treatment paradigm is mostly similar to that of Atopic Dermatitis. Therefore, the current treatment of CD is mainly dominated by the use of off-label therapies, which includes Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids and Others (Antiseptics, Topical Antibiotics, Phototherapy and Other Immunosupressants).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Contact Dermatitis, Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution, Gender-specific Diagnosed Prevalent Population of Contact Dermatitis, Age-specific Diagnosed Prevalent Population of Contact Dermatitis and Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
This section provides glimpse of the Contact Dermatitis (CD) epidemiology in the 7MM.
The epidemiology segment also provides the Contact Dermatitis (CD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The drug chapter segment of the Contact Dermatitis (CD) report encloses the detailed analysis of Contact Dermatitis (CD) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Contact Dermatitis (CD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Contact Dermatitis (CD) Emerging Drugs
EB01 Cream: Edesa Biotech
EB01 is a novel sPLA2 inhibitor for the topical treatment of chronic ACD. The sPLA2 inhibitors are designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred. The drug inhibits sPLA2 from degrading phospholipids to produce arachidonic acid. Arachidonic acid is processed via the LOX-COX pathway to generate several pro-inflammatory signalling molecules. The drug exerts its anti-inflammatory activity upstream of currently approved NSAIDs, which target the LOX-COX pathway. The FDA accepted Edesa's investigational new drug (IND) application of EB01 for CD patients in November 2018. In June 2019, Edesa Biotech and Stellar Biotechnologies completed share exchange agreement. The combined company, called Edesa Biotech, thereafter, focused on the development and advancement of innovative treatments for dermatological and gastrointestinal indications. In December 2019, the company reported that EB01 had demonstrated positive safety data in healthy volunteers participating in its ongoing phase IIb clinical study in chronic ACD. Considering this positive result, the company expanded the phase IIb dermatitis study to patients with facial lesions. Currently, the drug is still being investigated in phase II clinical developmental trial in the United States for CD.
Product detail in the report…
PDC-APB: Hapten Sciences
PDC-APB is a small molecule that acts like a vaccine to prevent the excruciating itching and rash (CD) caused by exposure to urushiol (yoo-ROO-she-ol) oil in poison ivy, poison oak, and poison sumac plants. Hapten licensed PDC-APB from the University of Mississippi in 2010. In 2015, the company had filed an Investigational New Drug (IND) application of PDC-APB for CD caused by poison ivy, poison oak, and poison sumac plants. The drug has already completed its phase I trial in January 2018 and in June 2019, Hapten Sciences published data regarding attainment of a fourth patent by the University of Mississippi for its investigational product that could prevent the painful itching and rash due to exposure to poison ivy, poison oak, and poison sumac.
Product detail in the report…
According to the American Academy of Allergy Asthma and Immunology (AAAAI), the CD is a common skin problem that occurs in ~15-20% of people. It can pose a significant financial burden with direct and indirect costs from lost time off work and school. CD can either be of allergic (ACD) type or irritant (ICD) type. Out of these two, ICD is more common (80%) and can occur in anyone, especially after repeated exposure. Additionally, in 2004, the Society of Investigative Dermatology revealed that ~72.3 million people were suffering from CD in the United States, representing one of the top five most economically burdensome skin diseases.
Since there are no approved therapies for CD, the market is mainly dominated by the use of off-label prescription drugs. Treatments for CD include Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids, and Others (Antiseptics, Topical Antibiotics, Phototherapy, and Other Immunosupressants). However, topical corticosteroids remain the mainstay or the first-line treatment option for CD while phototherapy and systemic immune modulators form the second-line treatment option for the indication.
The American Academy of Allergy, Asthma, and Immunology (AAAAI) has published separate diagnostic and management guidelines for both CD and atopic dermatitis (AD). As per these guidelines, the treatment pattern of both the indications was quite similar. Even though the pathophysiology of AD and CD are extremely different as AD is an immunodeficiency disorder and CD is contact triggered disorder, but the signs and symptoms of both the diseases are quite similar that justifies the same prescription pattern as well. Keeping this in mind, the US CD market forecast considers AD prescription pattern.
However, the current emerging market of CD does not possess a robust pipeline. There is only one therapy, EB01 Cream, which is in its phase II developmental stage. Additionally, there is another therapy, namely, PDC-APB that has completed its phase I trial and was licensed by Hapten from the University of Mississippi in 2010. The phase I trial of PDC-APB was completed in January 2018 itself; however, the results of this trial has not been published yet. Therefore, Hapten's PDC-APB has not been considered in the forecast model of CD report.
This section includes a glimpse of the Contact Dermatitis (CD) 7MM market.
This section provides the total Contact Dermatitis (CD) market size and market size by therapies in the United States.
The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Contact Dermatitis (CD) market size and market size by therapies in Japan are provided.
This section focusses on the rate of uptake of the potential drugs recently launched in the Contact Dermatitis (CD) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Contact Dermatitis (CD) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Contact Dermatitis (CD) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Contact Dermatitis (CD) emerging therapies.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Contact Dermatitis (CD) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Current Treatment Scenario, Marketed Drugs and Emerging Therapies: